Article

Sealant being studied for clear corneal wound closure

A new sealant (ReSure, Ocular Therapeutix) will be studied for clear corneal incision closure after cataract extraction or IOL placement.

Bedford, MA-Ocular Therapeutix has completed enrollment for the pivotal clinical trial of a polyethylene glycol-based hydrogel (ReSure) to close clear corneal wounds after cataract extraction or IOL placement.

The company enrolled 488 patients at 24 sites throughout the United States in an effort to gain premarket approval from the FDA.

The randomized, parallel-arm clinical trial is investigating the safety and efficacy of the sealant, which is applied as a liquid and then gels to form a barrier on the ocular surface. If approved, it would be an alternative to the stromal hydration used by ophthalmologists to prevent postoperative fluid egress on clear corneal incisions.

“A product such as this may prompt physicians to re‐evaluate how they deal with their surgical wounds at the conclusion of each cataract procedure,” said Ralph Chu, MD, principal investigator at Chu Vision Institute, Bloomington, MN.

Amar Sawhney, PhD, president and chief executive officer of Ocular Therapeutix, said the company looks forward to submitting the study data to the FDA in hopes of the product being approved for use in the United States.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
© 2025 MJH Life Sciences

All rights reserved.